Tsukuba Research Laboratories, Eisai Co., Ltd., Tokodai,
Tsukuba-shi, Ibaraki 300-26, Japan (O.T., T.H.) and
Faculty of
Pharmaceutical Sciences, The University of Tokyo, Hongo, Bunkyo-ku,
Tokyo 113, Japan (H.S., Y.S.)
The hepatic uptake of glucuronic acid and sulfate conjugates of
6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)
benzothiazole (E3040), a dual inhibitor of 5-lipoxygenase and
thromboxane A2 synthetase, was investigated in rats. The
biliary excretion clearance values for the glucuronide and the sulfate,
obtained after i.v. administration of E3040, were similar and
corresponded to approximately 30% of the hepatic blood flow rate. The
influx clearance values of E3040 conjugates in the presence of 3%
bovine serum albumin, measured by a multiple indicator dilution method
in the perfused liver, were 1.20 ml/min/g liver for the glucuronide and
0.74 ml/min/g liver for the sulfate, which were twice and equal to the
normal hepatic plasma flow rate, respectively, which suggests the
presence of an efficient transport system(s). The uptake of E3040
conjugates into the isolated hepatocytes is mediated by
Na+-independent active transport system(s), which is
inhibited by dibromosulfophthalein and bile acids. The uptake for the
sulfate had high-affinity and high-capacity transport activity
(Km = 25 µM; Vmax = 7.8 nmol/min/106 cells) compared with that for the glucuronide
(Km = 59 µM; Vmax = 2.2 nmol/min/106 cells). The uptakes of E3040 conjugates
(glucuronide, sulfate) exhibited a mutual competitive inhibition. It is
suggested that both conjugates share a multispecific organic anion
transporter located on the sinusoidal membrane.
 |
Introduction |
Conjugative metabolism, such as
glucuronidation and sulfation, is an important pathway for the
inactivation or detoxification of xenobiotics. On the other hand,
conjugative metabolites of certain drugs with pharmacologically active
(such as the 6-glucuronide of morphine; Osborne et al.,
1988
) or toxic (such as the glucuronides of anti-inflammatory drugs;
Spahn-Langguth and Benet, 1992
) properties have been reported. In such
cases, the disposition of metabolites, as well as the parent drug,
should be considered to identify any pharmacological and/or toxic
effect. However, it is difficult to predict the disposition of formed
metabolites based on the kinetics of preformed metabolites, because of
the uneven distribution of enzymes along the sinusoid, as well as the
lower membrane permeability of the metabolites compared with the parent
ligands. Pang (1985)
and Pang et al. (1992)
quantitatively
evaluated the kinetics of formed and preformed metabolites after
administration of parent ligands and preformed metabolites,
respectively. We have also investigated the disposition of conjugative
metabolites (Miyauchi et al., 1988
; Sato et al.,
1986
; Shimamura et al., 1993
).
In previous studies, we reported the disposition of glucuronide and
sulfate of E3040, a novel dual inhibitor of 5-lipoxygenase and
thromboxane A2 synthetase, after administration of E3040 by in vivo and by the liver perfusion experiments in rats
(Takenaka et al., 1995a
,b
). We showed that E3040 conjugates
were excreted efficiently into the bile. With single-pass steady-state
liver perfusion, the hepatic clearance of E3040 was found to be limited by hepatic blood flow, and the formed conjugates were concentratively excreted into bile. Furthermore, studies with bile canalicular membrane
vesicles suggested that the biliary excretion of glucuronide across the
bile canalicular membrane was mediated by the primary active transport
system, whereas that for the sulfate was mediated by another transport
system (Takenaka et al., 1995b
). This result suggested
that the carrier-mediated transport systems across the bile
canalicular membrane were one of the reasons for the efficient biliary
excretion of E3040 conjugates.
Because we found extrahepatic formation of E3040 conjugates in in
vivo experiments, an additional factor for the efficient biliary
excretion of E3040 conjugates may be the hepatic uptake mechanism(s)
located on the sinusoidal membrane. It is possible that a specific
transport mechanism is present for the hepatic uptake of E3040
conjugates, which are organic anions. Cumulative evidence suggests that
the nonbile acid organic anions are taken up into the liver
via the Na+-independent transport system, which
is defined as a multispecific organic anion transporter (Meier, 1988
).
Substrates for this transport system include bilirubin,
bromosulfophthalein, indocyanine green (Laperche et al.,
1981
; Paumgartner and Reichen, 1976
; Scharschmidt et al.,
1975
; Schwenk et al., 1976
; Wolkoff et al., 1987
;
Yamazaki et al., 1992
),
-lactam antibiotics such as
benzylpenicillin (Tsuji et al., 1986
), the hydroxymethyl
glutaryl coenzyme A reductase inhibitor pravastatin (Yamazaki et
al., 1993
) and DBSP (Blom et al., 1981
), although the
driving force of this transport system still remains to be clarified
(Potter et al., 1987
; Wolkoff et al., 1987
). The
cDNA which encodes the Na+-independent transport system was
previously cloned with an expression cloning technique in Xenopus
laevis oocytes (Jacquemin et al., 1994
).
Many reports have thus been published on the hepatic uptake of nonbile
acid organic anions; however, little attention has been given to the
hepatic uptake of conjugative xenobiotic metabolites. The uptake and
efflux of glucuronide and sulfate of acetaminophen across the plasma
membrane of hepatocytes are mediated by carrier-mediated transport
system(s) (Iida et al., 1989
; Studenberg and Brouwer, 1993
).
The sulfate conjugates of harmol and 4-methylumbelliferone are
transported into hepatocytes via Na+-independent
transport systems (Hassen et al., 1996
; Sundheimer and
Brendel, 1983
). In addition, the uptake of glucuronides (harmol glucuronide and glycyrrhizin) are also mediated by active transport systems (Ishida et al., 1993
; Sundheimer and Brendel, 1983
).
In the present study, we quantitatively evaluated the disposition of
E3040 glucuronide and sulfate in rats in in vivo and in vitro experiments. Furthermore, the transport mechanism
was also examined with use of the isolated hepatocytes.
 |
Materials and Methods |
Materials.
Unlabeled and 14C-labeled E3040 was
synthesized in our laboratories (Tsukuba, Japan) (Hibi et
al., 1994
). The radiochemical purity of [14C]E3040,
determined by HPLC, was 98.7%, and the specific activity was 50.9 µCi/µmol. 125I-Labeled BSA was purchased from New
England Nuclear Corp. (Boston, MA). DBSP was obtained from
Societé d'Etudes et de Recherches Biologiques (Paris, France).
Cholate, taurocholate, PCMBS, DIDS, rotenone and BSA (fraction V) were
purchased from Sigma Chemical Co. (St Louis, MO). FCCP was purchased
from Aldrich Chemical Co. (Milwaukee, WI). The chemical structure of
E3040 and its conjugates (glucuronide and sulfate) is shown in figure
1.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 1.
Plasma concentration-time profiles of E3040
conjugates after i.v. injection to male SD rats. After the i.v.
injection of [14C]E3040 glucuronide (2 µCi/0.04 µmol,
left panel) or [14C]E3040 sulfate (2 µCi/0.04 µmol,
right panel) to male SD rats, blood was collected at specific times to
determine the concentration of conjugates by TLC. Each point and
vertical bar represents the mean ± S.E. of three different
experiments. , glucuronide; , sulfate.
|
|
The glucuronide of [14C]E3040 was prepared by incubating
[14C]E3040 in rat liver microsomes. The reaction mixture
contained 0.1 M Tris-HCl at pH 7.4, 5 mM MgCl2, 1 mM
D-saccharic acid-1,4-lactone, 0.01% (v/v) Triton X-100,
0.2 mg/ml rat liver microsomes and 50 µCi (1 µmol)
[14C]E3040 in a final volume of 0.9 ml. The assay was
started by adding 0.1 ml of 30 mM UDP-glucuronic acid and incubated for
60 min at 37°C. For the sulfate of [14C]E3040, the
reaction mixture contained 0.1 M potassium phosphate buffer (pH 7.4), 3 mM 2-mercaptoethanol, 5 mM MgCl2, 0.2 mg/ml rat liver
cytosol and 50 µCi (1 µmol) [14C]E3040 in a final
volume of 0.9 ml. The assay was started by adding 0.1 ml of 2 mM
3
-phosphoadenosine-5
-phosphosulfate and incubated for 60 min at
37°C. Both assays were stopped by adding 5 ml CHCl3.
After centrifugation the aqueous layer which contained the E3040
conjugates was lyophilized. E3040 conjugates were purified from the
lyophilized sample by HPLC. E3040 conjugates labeled with
14C were checked for purity by HPLC and confirmed to be
more than 99% pure. HPLC analysis was performed on a YMC AM-312 column
(C18, 5 µm, 150 mm × 6 mm internal diameter). The
mobile phase consisted of MeOH/water/trifluoroacetic acid (100:900:1)
(solvent A) and MeOH/water/trifluoroacetic acid (700:300:1) (solvent
B). A linear gradient was run from 0 to 30 min to increase the amount
of solvent B from 10 to 60%, followed by a 5-min elution with 60%
solvent B, and a reverse gradient was run from 35 to 40 min to reduce the solvent B content to 10% again. The chromatographic analysis was
performed at a flow rate of 1 ml/min. [14C]E3040
conjugates were identified by means of TLC and HPLC with previously
prepared unlabeled E3040 conjugates as standards. The structure of the
unlabeled E3040 conjugates was determined by nuclear magnetic resonance
and mass spectrometry. Other chemicals used were commercially available
and of reagent grade.
Male SD rats (250-330 g) from Japan Laboratory Animals Inc. (Tokyo,
Japan) were used.
In vivo study.
The SD rats (n = 3) were lightly anesthetized with diethyl ether, and the femoral artery
and vein were cannulated with polyethylene tubing (PE-50) for blood
sampling and ligand administration, respectively. The common bile duct
was also cannulated with PE-10 to collect bile specimens. Rats were
housed in metabolic cages during the in vivo study to obtain
arterial blood, bile and spontaneous urine specimens. The rats were
allowed to recover from anesthesia before the initiation of the
experiment. [14C]E3040 glucuronide or sulfate (2 µCi/0.04 µmol) in saline was injected intravenously through the
femoral vein cannula. Blood, bile and urine specimens were obtained at
specified times. At each time point, we collected 100 µl of arterial
blood.
Analysis of specimens obtained from the in vivo study
and the pharmacokinetic analysis.
Plasma, bile and urine specimens
were analyzed by TLC as described previously (Takenaka et
al., 1995a
). For individual rats, the AUC
for E3040
conjugates was calculated as the zero-order moment of the time profiles
for plasma concentration. Each CLtot of the E3040
conjugates was calculated by dividing the dose by the
AUC
value. CLbile and CLrenal
values for E3040 conjugates were calculated by dividing the cumulative
amount of E3040 conjugates excreted into the bile and the urine
(Xbile and Xurine, respectively) by the
corresponding AUC
value. CLu,renal was
calculated by dividing the CLrenal by the corresponding
plasma unbound fraction of each conjugate (the value of glucuronide and
sulfate was 0.379 and 0.0613, respectively; Takenaka et al.,
1995a
).
Estimation of LUR from in vivo experiments.
The
LUR, i.e., the fraction of [14C]E3040
conjugates extracted by the liver during a single passage, was measured
in vivo (Liu et al., 1992
; Pardridge et
al., 1985
). The SD rats were lightly anesthetized with diethyl
ether, and the hepatic artery was ligated. A 200-µl volume of
[3H]inulin (2 µCi), as an extracellular reference, and
[14C]E3040 glucuronide or sulfate (0.2 µCi/0.004
µmol) in rat plasma or 3% BSA in Krebs-Ringer bicarbonate buffer (pH
7.4) were injected as a bolus into the portal vein. After 18 sec, the
liver was excised, a portion of the liver weighed and the radioactivity
counted in a liquid scintillation spectrophotometer (LSC-3500, Aloka
Co., Tokyo, Japan). The LUR of E3040 conjugates was obtained by the following equation:
|
(1)
|
where XE3040 conjugates and Xinulin are
the radioactivity of the E3040 conjugates and inulin in the liver after
administration of the mixture of E3040 conjugates and inulin,
respectively.
Liver perfusion study (MID method).
All isolated liver
procedures were performed as reported previously (Miyauchi et
al., 1987
). The perfusate consisted of 3% BSA in Krebs-Ringer
bicarbonate buffer (pH 7.4), and the flow rate was 30 ml/min. After a
stabilization period of approximately 15 min, a 180-µl volume of
125I-labeled BSA (0.1 µCi), as an extracellular
reference, and [14C]E3040 glucuronide (0.5 µCi/0.01
µmol) or sulfate (0.7 µCi/0.013 µmol) were injected
simultaneously as a bolus into the portal vein. Subsequently, the
hepatic venous outflow was collected at 1-sec intervals during a 20-sec
period with a turntable; then the effluent was collected at 10 sec up
to 60 sec. The outflow specimens were analyzed by TLC by the same
method as used for the in vivo study. The effluent dilution
curves were analyzed based on the distributed model (Bass and Keiding,
1988
) by a method reported previously (Miyauchi et al.,
1987
; Sato et al., 1988
; Tsao et al., 1986
) to
obtain the Kinf, the Keff
and the Kseq for total E3040 conjugates. We
calculated the PSinf by multiplying the
Kinf by Vext.
Vext is the volume accessible to the
extracellular reference during its passage through the liver, which can
be estimated by multiplying the flow rate by the mean transit time of
125I-labeled BSA (Miyauchi et al., 1987
). The
ratio of the AUC
of E3040 conjugates to that of
125I-labeled BSA was defined as the hepatic availability
(F), and the extraction ratio was calculated as 1
F.
Cell preparation.
Hepatocytes were isolated from SD rats
(250-330 g) by the procedure of Baur et al. (1975)
. After
isolation, the hepatocytes were suspended (2 × 106
cells/ml) at 0°C in albumin-free Krebs-Henseleit buffer supplemented with 12.5 mM HEPES (pH 7.4). Cell viability was routinely checked by
the trypan blue (0.4%, wt/vol) exclusion test, and only hepatocytes exhibiting more than 90% viability were used.
Uptake study.
The cell suspension (2 × 106
cells/ml) was preincubated in the medium (albumin-free Krebs-Henseleit
buffer supplemented with 12.5 mM HEPES, pH 7.4) for 3 min at 37°C.
The uptake of [14C]E3040 glucuronide or sulfate was
initiated by adding the ligand to the preincubated cell suspension. The
final concentration of [14C]E3040 conjugates was 2.5 µM, i.e., the isotope concentration for the conjugates was
0.12 µCi/ml. At designated times, the reaction was terminated by
separating the cells from the medium by centrifugal filtration
(Yamazaki et al., 1992
), and the radioactivity in both cells
and medium was determined in a liquid scintillation spectrophotometer (LSC-3500, Aloka Co., Tokyo, Japan). For inhibition studies, the cell
suspension was preincubated with either sulfhydryl reagent (100 µM
PCMBS), metabolic inhibitors (30 µM rotenone or 2 µM FCCP) or an
anion-exchange inhibitor (100 µM DIDS) for 3 min at 37°C before
adding [14C]E3040 conjugates. To determine the inhibitory
effect of organic anions, either DBSP, unlabeled E3040 conjugate,
taurocholate or cholate was added to the cell suspension simultaneously
with [14C]E3040 conjugate. The uptake of
[14C]E3040 conjugates was corrected for the adherent
fluid volume (2.0 µl; Yamazaki et al., 1992
).
Intracellular space (4.3 µl) was considered when the C/M ratio was
calculated. The initial uptake velocity (V0) was
calculated by linear regression on data points taken at 15 and 60 sec.
Determination of kinetic parameters.
The kinetic parameters
for E3040 conjugate uptake were estimated by use of the following
equation:
|
(2)
|
where V0 is the initial uptake rate of
E3040 conjugates (nmol/min/106 cells), S is the
E3040 conjugate concentration in the medium (µM),
Km is the Michaelis constant (µM),
Vmax is the maximum uptake rate
(nmol/min/106 cells) and Pdif is the
nonspecific uptake clearance (µl/min/106 cells). This
equation was fitted to the uptake data sets by an iterative nonlinear
least-squares method by use of a MULTI program (Yamaoka et
al., 1981
) to obtain estimates of kinetic parameters. The input
data were weighted as the reciprocal of the square of the observed
values, and the algorithm used for the fitting was the Damping Gauss
Newton Method (Yamaoka et al., 1981
). To compare with the
PSu,inf from LUR and liver perfusion study, the
PSu,inf (ml/min/g liver), based on the kinetic parameters
obtained by the described fitting procedure, was calculated by the
following equation.
|
(3)
|
where
= 1.2 × 108 (cells/g liver; Zhalten
and Stratman, 1974
) and
(1 × 106 cells) is the
factor to correct the dimension of Vmax from
(nmol/min/106 cells) to (nmol/min/cell).
To determine the inhibition constant (Ki) of
DBSP and E3040 conjugates on the uptake of [14C]E3040
conjugates, saturable uptake of [14C]E3040 glucuronide
and sulfate was examined in the presence and absence of inhibitors. The
data were fitted simultaneously to equations 2 and 4 to calculate the
kinetic parameters, assuming the competitive inhibition.
|
(4)
|
where I is the concentration of the inhibitors.
Estimation of influx clearance from the in vivo
experiment.
Based on the LUR values of E3040 conjugates obtained
in vivo, the PSu,inf was calculated by use of
either the distributed model (Bass, 1980
; Bass and Keiding, 1988
) or
dispersion model (Roberts and Rowland, 1986a
; Roberts et
al., 1988
). The distributed model is:
|
(5)
|
The dispersion model is:
|
(6)
|
where a = (1 + 4 · RN · DN)1/2;
RN = fb · PSu,inf/Qb;
DN = 0.17; Qb is the
hepatic blood flow rate and fb is the blood
unbound fraction. The hepatic blood flow rate was assumed to be 1.5 ml/min/g liver, considering the previously reported hepatic blood flow rate (15 ml/min/rat) (Lutz et al., 1977
). In addition,
Pardridge and Mietus (1979)
reported that the hepatic blood flow rate
as 1.4 ml/min/g liver. The fb value was
calculated by dividing the fp (glucuronide,
0.379; sulfate, 0.0613) value by the blood/plasma concentration ratio
(RB). The RB value is
0.593 for the glucuronide and 0.627 for the sulfate. A
DN value of 0.17 was used based on the findings
previously reported by Roberts and Rowland (1986b)
that this value gave
a good correlation between in vitro microsomal enzyme
activity and whole organ hepatic elimination analyzed with a dispersion
model.
 |
Results |
In vivo study.
Plasma concentration-time profiles
of E3040 conjugates after i.v. injection of [14C]E3040
glucuronide or sulfate administered to rats are shown in figure
1. Neither glucuronide formed from the sulfate nor
sulfate formed from the glucuronide was observed in plasma. The
CLtot values of the glucuronide and sulfate were 56.3 ml/min/kg and 19.7 ml/min/kg, respectively (table 1).
The cumulative biliary and urinary excretion rates of E3040 conjugates
are shown in figure 2. The cumulative amount of
glucuronide excreted into the bile up to 3 hr after the i.v. injection
of [14C]E3040 glucuronide was approximately 95%. After
dosing of [14C]E3040 sulfate, the biliary and urinary
excretion rates of the sulfate up to 22 hr were approximately 60 and
21%, respectively (table 1), and an unknown metabolite (M1) was
detected in the bile as 7% of the dose (fig. 2). As shown in table 1,
the CLbile and CLrenal values of the
glucuronide and sulfate were 53.5 and 11.6 ml/min/kg and 2.8 and 3.9 ml/min/kg, respectively. This indicated that the major clearance of
E3040 conjugates was by biliary excretion. The CLu,renal
corrected by the plasma unbound fraction was 7.17 ml/min/kg for the
glucuronide and 63.8 ml/min/kg for the sulfate (table 1). The
CLu,renal of the sulfate was much greater than the
glomerular filtration rate in rats (approximately 5 ml/min/kg), which
suggested that a secretion mechanism contributes to the urinary
excretion of the sulfate.
View this table:
[in this window]
[in a new window]
|
TABLE 1
Disposition of E3040 glucuronide or sulfate in SD rats
The values were calculated from the data shown in figures 1 and 2.
CLbile and CLrenal were calculated by dividing the
amount of conjugates excreted into the bile and the urine by the
AUC value. CLu,renal was calculated by dividing
CLrenal by the respective unbound fraction of each conjugate
(glucuronide, 0.379; sulfate, 0.0613). All values are given as the
mean ± S.E. of three different experiments.
|
|

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 2.
Cumulative biliary and urinary excretion of
E3040 conjugates in male SD rats. [14C]E3040 glucuronide
(2 µCi/0.04 µmol, left panel) or [14C]E3040 sulfate
(2 µCi/0.04 µmol, right panel) were injected intravenously as a
bolus to male SD rats. Top and bottom panels show the time course of
the cumulative biliary and urinary excretion of E3040 conjugates,
respectively. Each point and vertical bar represents the mean ± S.E. of three different experiments. , glucuronide; , sulfate;
, M1.
|
|
LUR study.
The LUR calculated by equation 1 is shown in table
2. The LUR value of the glucuronide was approximately
0.65 in rat plasma and 3% BSA injected solution, and that of the
sulfate was 0.61 in plasma and 0.53 in BSA solution.
View this table:
[in this window]
[in a new window]
|
TABLE 2
The LUR of E3040 conjugates
LUR values were calculated by equation 1. All values are given as the
mean ± S.E. of three different experiments.
|
|
MID study.
Figure 3 shows the outflow dilution
curves of [14C]E3040 glucuronide or sulfate and
125I-labeled BSA, used as the extracellular reference. The
extraction ratios were 0.31 and 0.13 for the glucuronide and sulfate,
respectively (table 3). The dilution curve was analyzed
to determine the PSinf, Keff and
Kseq for total E3040 conjugates and the
PSu,inf of E3040 conjugates (table 3). The
PSinf value of the glucuronide was 1.20 and that of the
sulfate was 0.744. The PSu,inf value of the sulfate was
approximately 2.5 times higher than that of the glucuronide (table 3).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
Normalized hepatic venous outflow dilution curves of
[14C]E3040 conjugates. Rat liver was perfused with
erythrocyte-free perfusate for 15 min before a bolus injection of
125I-labeled BSA (0.1 µCi) and [14C]E3040
glucuronide (0.5 µCi/0.01 µmol) or 125I-labeled BSA
(0.1 µCi) and [14C]E3040 sulfate (0.7 µCi/0.013
µmol) into the portal vein. The total effluent from the hepatic vein
was collected at 1-sec intervals over a 20-sec period and then at 10 sec up to 60 sec (left panel, glucuronide; right panel, sulfate).
Values on the y-axis are outflow concentrations that have
been normalized for the injected dose. Each point and vertical bar
represents the mean ± S.E. of five different experiments. ,
glucuronide; , sulfate; , , BSA.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 3
MID analysis
The parameter values were obtained by analyzing the data shown in
figure 3. The PSinf, Keff and
Kseq for E3040 conjugates were calculated by the
conventional method. (See details in the text.) All parameters are
given as the mean ± S.E. of five different experiments.
|
|
The uptake of E3040 conjugates by isolated rat hepatocytes.
The time course of [14C]E3040 glucuronide and sulfate
(2.5 µM) uptake by isolated rat hepatocytes is shown in figure
4. The C/M ratio at 15 min was 40 for the glucuronide
and 200 for the sulfate. Previously, we determined the unbound fraction
of E3040 conjugates in the liver by steady-state perfusion of
[14C]E3040 (Takenaka et al., 1995b
). Because
the unbound fraction values in the hepatic cytosol were 0.36 and 0.062 for E3040 glucuronide and sulfate, respectively, the unbound C/M ratio
values at 15 min were calculated to be 14.4 and 12.4 for the
glucuronide and sulfate, respectively, which indicated the presence of
highly concentrative uptake of E3040 conjugates.

View larger version (9K):
[in this window]
[in a new window]
|
Fig. 4.
Time course for the uptake of
[14C]E3040 conjugates (2.5 µM) by isolated rat
hepatocytes. and , the C/M ratio for the glucuronide (left
panel) and the sulfate (right panel), respectively. Each point and
vertical bar represents the mean ± S.E. from three
determinations.
|
|
A concentration dependence was observed in the E3040 conjugates uptake,
and the Eadie-Hofstee plots of the uptake data indicated the presence
of two components (fig. 5). The kinetic parameters are
shown in table 4. Comparison of the kinetic parameters
for E3040 conjugates revealed that the uptake of the sulfate was
composed of a high affinity (1/Km) and high
capacity (Vmax) transport characteristics compared with the glucuronide (table 4).

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 5.
Concentration dependence for the uptake of E3040
glucuronide (left panel) and sulfate (right panel) by isolated rat
hepatocytes. The isolated hepatocytes were incubated in the medium
containing 2.5 µM of [14C]E3040 conjugates with or
without unlabeled conjugates. Each point and vertical bar represents
the mean ± S.E. from three different preparations. Upper panels,
the relationship between the initial uptake velocity
(V0) and the concentration of E3040 conjugates in the incubation medium (S). ---------, the least-squares
fit of the data to equation 2; ... ., the estimated nonspecific
diffusion calculated with the value of the nonspecific uptake clearance
(Pdif); - - -, the theoretical curve of
saturable uptake. The same uptake data are shown as Eadie-Hofstee plots
in the lower panels.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 4
Kinetic parameters for uptake of E3040 glucuronide or sulfate by
isolated rat hepatocytes
The data shown in figure 5 were analyzed to determine the kinetic
parameters by use of equation 2.
|
|
The uptake of both conjugates exhibited a marked temperature dependence
(fig. 6); the V0 of the
glucuronide decreased to 31% (at 27°C) and 13% (at 0°C) of the
control (37°C), and that of the sulfate was reduced to 40% at 27°C
and 11% at 0°C. The Q10 value, which is the
ratio of V0 at 37°C to that at 27°C, was
estimated to be 3.2 and 2.5 for the glucuronide and sulfate,
respectively. The uptake of E3040 conjugates were also decreased
significantly by the sulfhydryl-modifying reagent (PCMBS) and metabolic
inhibitors (rotenone and FCCP) (fig. 6). DIDS, an anion-exchange
inhibitor, reduced the uptake of E3040 conjugates (fig. 6).
Na+ replacement by choline+ had no marked
effect on the uptake of E3040 conjugates (fig. 6).

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of temperature, sulfhydryl-modifying reagent,
ion substitution, metabolic inhibitors and DIDS on the initial uptake of [14C]E3040 glucuronide (left panel, 2.5 µM) or
sulfate (right panel, 2.5 µM) by isolated rat hepatocytes. Each bar
represents the mean ± S.E. of four determinations in two separate
preparations. ** P < .001, * P < .01 by Student's
t test.
|
|
We also studied the effects of another organic anion, DBSP, and bile
acids, taurocholate and cholate, on the uptake of E3040 conjugates. The
V0 of E3040 conjugates was inhibited by all
these compounds in a concentration-dependent manner (fig.
7). The uptake of the glucuronide was reduced to 10 to
20% of the control by the presence of these inhibitors (100 µM),
whereas the inhibitors had less effect on sulfate uptake (fig. 7).
Glucuronide and sulfate also exhibited a mutual inhibition of uptake
(fig. 7).

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of DBSP, cholate, taurocholate and E3040
conjugates on the initial uptake of [14C]E3040
glucuronide (left panel, 2.5 µM) or sulfate (right panel, 2.5 µM)
by isolated rat hepatocytes. Each bar represents the mean ± S.E.
of four determinations in two separate preparations.
|
|
The inhibition by DBSP and E3040 conjugates on E3040 glucuronide and
sulfate uptake was further characterized. The Eadie-Hofstee plots in
the presence or absence of these inhibitors are shown in figure
8. DBSP (5 µM) and E3040 sulfate (15 µM) were used
as inhibitors for E3040 glucuronide uptake, whereas DBSP (5 µM) and E3040 glucuronide (35 µM) were used for E3040 sulfate uptake. Because
the nonsaturable component of the uptake of E3040 conjugates may be
accounted for by the passive diffusion which was not affected the
inhibitor (fig. 8), the kinetic parameters for the uptake of E3040
conjugates in the presence and absence of inhibitors were
simultaneously fitted to equations 2 and 4, assuming the competitive
inhibition for the saturable component. The calculated curves obtained
from least-squares fit of data to the equation coincided with
experimental results (fig. 8). It was thus demonstrated that DBSP
competitively inhibited E3040 conjugates uptake, and that E3040
glucuronide and sulfate competitively inhibit each other's uptake. The
Ki values of DBSP were 8.4 µM and 5.4 µM for E3040 glucuronide and sulfate uptake, respectively (table
5). The Ki value of E3040 sulfate
for E3040 glucuronide uptake, and Ki value of
E3040 glucuronide for E3040 sulfate uptake were 6.3 µM and 66 µM,
respectively (table 5).

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 8.
Eadie-Hofstee plots for the uptake of
[14C]E3040 glucuronide (left panel) or sulfate (right
panel). To characterize the inhibition effect of DBSP on the uptake of
[14C]E3040 glucuronide and sulfate, the saturation of
[14C]E3040 conjugates was examined in the presence and
absence of 5 µM DBSP. In the same manner, the mutual inhibition
between E3040 glucuronide and sulfate was examined. Each point and
vertical bar represents the mean ± S.E. of four determinations
from two independent experiments, both of which were performed in
duplicate. ---------, the least-squares fit of the data which was
obtained by simultaneously fitting the data to equations 2 and 4; left
panel, saturation of the uptake of E3040 glucuronide: , absence of
inhibitors; , presence of DBSP (5 µM); , presence of E3040
sulfate (15 µM). Right panel, saturation of the uptake of E3040
sulfate: , absence of inhibitors; , presence of DBSP (5 µM);
, presence of E3040 glucuronide (35 µM).
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 5
Ki values of DBSP and the conjugates for the uptake
of E3040 glucuronide and sulfate
The saturable uptake of [14C]E3040 conjugates in the presence
and absence of inhibitors (fig. 8) was simultaneously fitted to equations 2 and 4 to determine the kinetic parameters. The uptake of
[14C]E3040 glucuronide was described by one saturable
(Km = 73.3 ± 15.3 µM;
Vmax = 2.51 ± 0.49 nmol/min/106 cells)
and one nonsaturable (Pdif = 4.41 ± 0.74 µl/min/106 cells) components. The uptake of
[14C]E3040 sulfate was described by one saturable
(Km = 28.5 ± 2.7 µM; Vmax = 8.96 ± 0.66 nmol/min/106 cells) and one nonsaturable
(Pdif = 5.51 ± 1.75 µl/min/106
cells) components. These Km, Vmax
and Pdif values for E3040 conjugates were not
significantly different from those reported in table 4.
|
|
Comparison of permeability (PSu,inf) in three different
experiments.
The hepatic influx clearance of E3040 conjugates
(PSu,inf) obtained from isolated hepatocytes, liver
perfusion (MID) and liver in vivo (LUR) are shown in table
6. The PSu,inf values of the glucuronide
were 2.64, 2.85, 4.19 and 4.92 ml/min/g liver for distributed (DB) or
dispersion (DP) model analysis of LUR, MID and isolated hepatocytes,
respectively, and these values were similar. The PSu,inf
values of the sulfate were 15.6 (DB), 16.7 (DP) and 11.5 (MID) ml/min/g
liver. The PSu,inf value obtained from isolated
hepatocytes, however, was 38.4 ml/min/g liver, which was approximately
three times higher than those from LUR and MID.
 |
Discussion |
In the present study, we investigated the disposition of E3040
glucuronide and sulfate in rats. The hepatic uptake mechanism of E3040
conjugates was also examined. The CLbile of E3040
conjugates was 54 ml/min/kg for the glucuronide and 12 ml/min/kg for
the sulfate; these values accounted for approximately 95% and 62% of
the CLtot for the glucuronide and sulfate, respectively
(table 1). This result indicates that the main clearance pathway of E3040 conjugates is biliary excretion. Absence of glucuronide or
sulfate in plasma, urine and bile after i.v. injection of the sulfate
and glucuronide, respectively (figs. 1 and 2 and table 1), suggests
that the deconjugation of E3040 may not take place, which was in marked
contrast to the conjugative metabolites of 4-methylumbelliferone and
harmol (Kauffman et al., 1991
; Miyauchi et al.,
1989
; Sundheimer and Brendel, 1983
). Because we found that a
demethylated metabolite of E3040 sulfate was present in bile after oral
administration of [14C]E3040 to rats and beagle dogs
(unpublished data), it is possible that the unknown metabolite,
detectable in the bile after i.v. injection of the sulfate, might be
the demethylated metabolite of the sulfate (fig. 2). The
CLbile value, calculated by considering the partition to
red blood cells, for the glucuronide (90 ml/min/kg) was almost the same
as the hepatic blood flow rate in rats (60-80 ml/min/kg), and that for
the sulfate (19 ml/min/kg) was approximately 30% of the hepatic blood
flow rate despite the plasma protein binding of the sulfate being 94%.
This indicates that E3040 conjugates are transported efficiently into
the liver followed by excretion into the bile. The finding that the
CLbile of the preformed and formed conjugates was almost
the same after i.v. injection of E3040 conjugates and E3040,
respectively, suggests that the specific transport mechanism of E3040
conjugates is also involved in the hepatic uptake process across the
sinusoidal membrane (Takenaka et al., 1995a
).
To further quantify the hepatic uptake of E3040 conjugates, MID studies
were performed. The PSu,inf of E3040 conjugates was estimated with perfused liver after a bolus injection (MID) of E3040
conjugates. As shown in table 3, the hepatic extraction ratios of the
glucuronide and sulfate were 0.31 and 0.13, respectively. Because the
hepatic extraction of E3040 was previously determined as 0.98 in
perfused liver under the same conditions (Takenaka et al.,
1995a
), the membrane permeability of E3040 conjugates are markedly
reduced compared with E3040. The PSinf values of the
glucuronide and sulfate, calculated by analysis of the dilution curves
(fig. 3) were twice and equal to the hepatic plasma flow rate in rats
(0.7 ml/min/g liver), respectively (table 3). Considering the unbound
fraction of E3040 conjugates, PSu,inf values of the glucuronide and sulfate were calculated to be 4.19 and 11.5 ml/min/g liver, respectively (table 3). Similar PSu,inf values were
obtained in LUR experiments (table 6). It is thus suggested that the
hepatic uptake of E3040 conjugates is mediated by specific uptake
mechanism(s), such as carrier-mediated active transport system(s),
because E3040 conjugates are efficiently taken up into the liver in
spite of their hydrophilic nature. We must be cautious in the
interpretation of LUR experiments, however, because LUR at 18 sec is a
function of not only the PSinf but also the elimination of
ligands from the tissue. To accurately determine PSinf from
LUR experiments, therefore, the time profiles for LUR values after
injection should be analyzed to determine LUR at time zero by
extrapolating the profiles. To evaluate the specific uptake
mechanism(s) of E3040 conjugates, the uptake by isolated rat
hepatocytes was investigated. The uptake characteristics of E3040
glucuronide and sulfate, which are highly concentrative (fig. 4),
saturable (fig. 5), temperature dependent (fig. 6) and sensitive to
metabolic inhibitors (fig. 6) demonstrated that E3040 conjugate uptake
is mediated by energy-dependent uphill transport. The uptake of E3040
conjugates consists of a saturable component and nonspecific diffusion
(fig. 5). The uptake affinity (1/Km) and uptake
capacity (Vmax) of the sulfate was 2.4 times and
3.5 times higher than those of the glucuronide and, consequently, the
saturable uptake clearance
(Vmax/Km) of the sulfate
was 8.5 times greater than that of the glucuronide (table 4), which
indicates that the intrinsic hepatic uptake ability of the sulfate is
higher than that of the glucuronide. The contribution of the
carrier-mediated uptake to the total uptake
(Vmax/Km)/(Vmax/Km + Pdif) in a linear range (i.e., at a
low concentration of conjugates) is estimated as 89% for the
glucuronide and 98% for the sulfate (table 4). Thus, E3040 conjugates
are considered to be taken up by the liver predominantly by
carrier-mediated mechanism(s).
The E3040 conjugate uptake is Na+-independent, as found for
nonbile acid organic anion uptake, and inhibited by the nonbile acid
organic anion DBSP and bile acids (taurocholate and cholate) in a
concentration-dependent manner (fig. 7). E3040 glucuronide and sulfate
also mutually inhibit each other's uptake (fig. 7). The inhibition of
DBSP and E3040 sulfate on E3040 glucuronide uptake and of DBSP and
E3040 glucuronide on E3040 sulfate uptake were competitive. The
Ki value of DBSP for the uptake of E3040 conjugates (8.4 and 5.4 µM) were similar to the
Km value of DBSP itself (Blom et al.,
1981
), which suggests that E3040 glucuronide, sulfate and DBSP might
share the transport carriers (table 5). Furthermore, the
Ki value of the glucuronide for the sulfate
uptake (66 µM) was also similar to the Km
itself (73 µM), whereas the Ki of the sulfate
for the glucuronide uptake was 6.3 µM, which is smaller than the
Km itself (28 µM) (table 5). It is possible that both conjugates may share a common transport carrier. At present,
however, we cannot explain the difference between the Ki and Km of the sulfate
in detail, and we cannot exclude the possibility of noncompetitive
inhibition for glucuronide uptake. Taken together, these results
suggest that E3040 conjugates may be taken up by hepatocytes
via an organic anion transport system, mediated by the
"Na+-independent multispecific organic anion
transporter" (Meier, 1988
), although the driving force of the uptake
mediated by Na+-independent multispecific organic anion
transporter has not yet been clearly identified. Furthermore, this
system recognizes not only nonbile acid organic anions but also bile
acids (taurocholate and cholate) as the substrate (Jacquemin et
al., 1994
). This result supports our present findings that the
uptake of E3040 conjugates is inhibited by bile acids (fig. 7).
Finally, the absolute values of PSu,inf determined from MID
studies and those from isolated hepatocytes should be compared. As
listed in table 6, the PSu,inf values for the glucuronide estimated from both studies were similar, whereas the
PSu,inf value for the sulfate from in vitro
experiments was 2.5 to 3 times higher than that from the perfused liver
(table 6); albumin-mediated transport, which was originally proposed by
Weisiger et al. (1981)
, was observed for the sulfate. These
results are consistent with our previous results; we determined the
PSu,inf values by use of the isolated hepatocytes for
several ligands whose degree of protein binding and membrane
permeability are significantly different each other, along with the
effect of albumin on the uptake of respective ligands in MID
experiments (Ichikawa et al., 1992
). Among the ligands
examined, the albumin-mediated transport was most extensive for
warfarin with the lowest fu (0.02) and highest PSu,inf
(higher than 140 ml/min/g liver) (Ichikawa et al., 1992
). Such phenomena were observed for diazepam, taurocholate, tolbutamide and salycylate whose unbound fraction and PSu,inf were
0.1 to 0.25 and 6 to 140 ml/min/g liver, respectively (Ichikawa
et al., 1992
). In contrast, the PSu,inf was
comparable between the two experimental systems for cefodizime with the
highest fu (0.56) and lowest PSu,inf (0.26 ml/min/g liver)
(Ichikawa et al., 1992
). The discrepancy of
PSu,inf for E3040 sulfate between the MID and isolated
hepatocyte studies, but not that for E3040 glucuronide, is consistent
with the previous results; much higher membrane permeability (38.4 for
the sulfate vs. 4.92 for the glucuronide), along with much
lower unbound fraction of the sulfate than of the glucuronide (0.06 for
the sulfate vs. 0.29 for the glucuronide) could be the cause
of the discrepancy.
Because the presence of albumin receptor was denied previously
(Weisiger et al., 1984
; Weisiger, 1985
), one of the possible hypotheses to account for these results is the assumption that the
rate-limiting process for the hepatic uptake of ligands with high
membrane permeability is the diffusion process through the UWL (Bass
and Pond, 1987
; Ichikawa et al., 1992
; Miyauchi et
al., 1993
; Weisiger et al., 1989
). However, because it
is reported that erythrocytes are being squeezed through the sinusoid
to erupt UWL (Barry and Diamond, 1984
; Holland et al., 1982
)
and that the UWL effect is more profound under in vitro
experimental conditions (Barry and Diamond, 1984
; Bass and Pond, 1987
;
Blouin et al., 1977
), the albumin-mediated transport cannot
absolutely be accounted for by this hypothesis. Further, elaborate
studies are required to reveal the mechanism for this phenomenon.
In conclusion, E3040 glucuronide and sulfate are efficiently excreted
into the bile, and the active transport system for hepatic uptake plays
an important role in the efficient biliary excretion of E3040
conjugates. It is suggested that the hepatic uptake of E3040 conjugates
is mediated via an Na+-independent multispecific
organic anion transport system.
Accepted for publication October 30, 1996.
Received for publication May 24, 1996.
E3040, 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole;
[14C]E3040, [2-14C]6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)
benzothiazole dihydrochloride ;
SD rats, Sprague-Dawley rats;
DBSP, dibromosulfophthalein;
HEPES, N-2-hydroxyethylpiperazine-N
-2-ethanesulfonic acid;
MID method, multiple indicator dilution method;
HPLC, high-performance liquid
chromatography;
BSA, bovine serum albumin;
TLC, thin-layer
chromatography;
AUC
, the area under the plasma
concentration-time profiles from zero to infinity;
CLbile, the biliary excretion clearance;
CLrenal, the urinary
excretion clearance;
CLu,renal, the unbound urinary
excretion clearance;
Xbile, the amount excreted into the
bile;
Xurine, the amount excreted into the urine;
CLtot, the total body clearance;
PSinf, the
influx clearance;
PSu,inf, the unbound influx clearance;
Kinf, the influx rate constant;
Keff, the efflux rate constant;
Kseq, the sequestration rate constant;
Km, Michaelis constant;
Vmax, maximal uptake rate;
Pdif, the nonspecific uptake clearance;
LUR, the
first-pass liver uptake ratio;
UWL, the unstirred water layer;
PCMBS, p-chloromercuriphenylsulfonic acid;
DIDS, 4,4
-diisothiocyanatostilbene-2,2
-disulfonic acid;
FCCP, carbonyl
cyanide-p-(trifluoromethoxy)-phenylhydrazone;
C/M, cell-to-medium concentration.